EBMT 2024 | MRD as a monitoring technique of alloSCT and CAR-T in AML/ALL
Felicitas Thol, MD, Hannover Medical School, Hannover, Germany, discusses emerging monitoring techniques in allogeneic stem cell transplantation (alloSCT) and CAR-T therapies for patients with acute myeloid leukemia (AML) and pediatric acute lymphoblastic leukemia (ALL). Measurable residual disease (MRD) can be utilized for patient selection and prognostication of alloSCT in adult AML. MRD also plays a significant role in CAR-T patient selection for pediatric ALL clinical trials. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Board for BMS, Novartis, AbbVie, Menarini, Rigel Honorarium: AbbVie, Astellas.
